

Special Issue

Treatment and Prognosis of Hematological Malignancies

Message from the Guest Editor

During the last two decades, we have witnessed a complete transformation in how we approach hematological diseases. A deeper understanding of the biology of specific hematological malignancies has exposed numerous novel therapeutic agents.

Monoclonal antibodies, bispecific T cell engagers, antibody–drug conjugates, as well as immunotoxins are increasingly used for cancer immunotherapy. Cellular immunotherapeutic agents, including the chimeric antigen receptor-engineered T cell (CAR-T) therapy and NK cell therapy, have fundamentally changed the landscape of hematological malignancies therapy from cytotoxic chemotherapy to biomarker-driven precision agents. In this Special Issue, “Treatment and Prognosis of Hematological Malignancies”, experts discuss recent innovations in this field and lay out the remaining key questions for the near future.

Guest Editor

Dr. Magdalena Witkowska

Department of Hematology, Medical University of Lodz, Lodz, Poland

Deadline for manuscript submissions

30 October 2026



Hematology Reports

an Open Access Journal
by MDPI

Impact Factor 1.9
CiteScore 2.3
Indexed in PubMed



mdpi.com/si/263808

Hematology Reports
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
hematolrep@mdpi.com

[mdpi.com/journal/
hematolrep](https://mdpi.com/journal/hematolrep)





Hematology Reports

an Open Access Journal
by MDPI

Impact Factor 1.9
CiteScore 2.3
Indexed in PubMed



[mdpi.com/journal/
hematolrep](https://mdpi.com/journal/hematolrep)



About the Journal

Message from the Editor-in-Chief

Hematology is a rapidly evolving discipline, central to understanding and treating disorders of the blood. *Hematology Reports* aims to provide an open platform for researchers and clinicians to share findings, insights, and innovations with the global scientific community. We encourage submissions that enhance clinical knowledge of blood disorders and their clinical management, from basic biology to translational and clinical studies. Through fostering collaboration and discussion, the journal seeks to advance knowledge and support improvements in both research and clinical practice.

Editor-in-Chief

Prof. Dr. Claudio Cerchione

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014
Meldola, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 26.3 days after submission; acceptance to publication is undertaken in 4.6 days (median values for papers published in this journal in the first half of 2026).